Do analysts recommend BDRX or AEON?

AEON Biopharma has a consensus target price of $1.10, suggesting a potential upside of 297.11%. Given AEON Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has stronger valuation and earnings, BDRX or AEON?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A AEON Biopharma N/A N/A -$36.63M -$4.42 N/A

Is BDRX or AEON more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A AEON Biopharma N/A N/A -994.63%

Do analysts rate BDRX or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BDRX or XTLB?

XTL Biopharmaceuticals has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A XTL Biopharmaceuticals $450K 12.37 -$6.97M -$0.64 N/A

Is BDRX or XTLB more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A

Do analysts prefer SNGX or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SNGX or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Soligenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix $120K 47.55 -$11.08M -$0.98 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is SNGX or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts rate BDRX or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BDRX or PMCB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Nuvilex N/A N/A -$19.42M -$3.00 N/A

Is BDRX or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Biodexa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Nuvilex N/A 0.25% 0.18%

Do analysts rate BDRX or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BDRX or CDIO?

Cardio Diagnostics has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Cardio Diagnostics $10K 555.89 -$6.50M -$2.92 N/A

Biodexa Pharmaceuticals (BDRX) Competitors

$0.89 -0.09 (-8.83%)

As of 10:49 AM Eastern

Compare

BDRX vs. AEON, XTLB, SNGX, PMCB, and CDIO

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? Biodexa Pharmaceuticals's main competitors and comparable companies include AEON Biopharma (AEON), XTL Biopharmaceuticals (XTLB), Soligenix (SNGX), Nuvilex (PMCB), and Cardio Diagnostics (CDIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

AEON Biopharma has a consensus target price of $1.10, suggesting a potential upside of 297.11%. Given AEON Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

In the previous week, AEON Biopharma had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.96 beat AEON Biopharma's score of 0.55 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Positive
AEON Biopharma	Positive

Summary

AEON Biopharma beats Biodexa Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to XTL Biopharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Biodexa Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals	N/A	N/A	N/A

XTL Biopharmaceuticals has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
XTL Biopharmaceuticals	$450K	12.37	-$6.97M	-$0.64	N/A

In the previous week, Biodexa Pharmaceuticals and Biodexa Pharmaceuticals both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 0.96 beat Biodexa Pharmaceuticals' score of 0.96 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Positive
XTL Biopharmaceuticals	Positive

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XTL Biopharmaceuticals beats Biodexa Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Soligenix has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Soligenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	47.55	-$11.08M	-$0.98	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Soligenix and Soligenix both had 2 articles in the media. Soligenix's average media sentiment score of 1.44 beat Biodexa Pharmaceuticals' score of 0.96 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Positive
Biodexa Pharmaceuticals	Positive

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 1.9% of Soligenix shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Soligenix and Biodexa Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Nuvilex?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex's return on equity of 0.25% beat Biodexa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Nuvilex	N/A	0.25%	0.18%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Biodexa Pharmaceuticals' score of 0.96 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Positive
Nuvilex	Very Positive

Summary

Nuvilex beats Biodexa Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Cardio Diagnostics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Cardio Diagnostics	$10K	555.89	-$6.50M	-$2.92	N/A

In the previous week, Cardio Diagnostics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Cardio Diagnostics and 2 mentions for Biodexa Pharmaceuticals. Cardio Diagnostics' average media sentiment score of 1.15 beat Biodexa Pharmaceuticals' score of 0.96 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Positive
Cardio Diagnostics	Positive

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cardio Diagnostics beats Biodexa Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$913K	$4.00B	$7.23B	$12.87B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	N/A	11.49	272.48	24.29
Price / Sales	N/A	1,304.68	608.54	79.97
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	0.01	16.72	13.12	6.25
Net Income	-$8.42M	-$22.76M	$3.47B	$348.11M
7 Day Performance	-29.29%	3.34%	2.05%	1.47%
1 Month Performance	-43.25%	11.53%	8.25%	4.70%
1 Year Performance	-96.88%	58.10%	26.26%	17.01%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.8068 of 5 stars	$0.89 -8.8%	N/A	-96.5%	$913K	N/A	N/A	20	Short Interest Decrease Gap Down
AEON AEON Biopharma	4.1223 of 5 stars	$0.25 -4.1%	$1.10 +349.0%	-66.8%	$6.20M	N/A	1.36	5
XTLB XTL Biopharmaceuticals	0.7951 of 5 stars	$3.23 +24.2%	N/A	N/A	$6.14M	$450K	N/A	N/A	Short Interest Decrease High Trading Volume
SNGX Soligenix	1.2433 of 5 stars	$0.40 +3.9%	N/A	-87.8%	$5.93M	$120K	N/A	20	Short Interest Decrease
PMCB Nuvilex	1.4339 of 5 stars	$0.52 -3.3%	N/A	-46.5%	$5.92M	N/A	N/A	4	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. AEON, XTLB, SNGX, PMCB, and CDIO

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Summary

How does Biodexa Pharmaceuticals compare to XTL Biopharmaceuticals?

Summary

How does Biodexa Pharmaceuticals compare to Soligenix?

Summary

How does Biodexa Pharmaceuticals compare to Nuvilex?

Summary

How does Biodexa Pharmaceuticals compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. AEON, XTLB, SNGX, PMCB, and CDIO

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Do analysts recommend BDRX or AEON?

Is BDRX or AEON more profitable?

Which has more volatility & risk, BDRX or AEON?

Do institutionals and insiders have more ownership in BDRX or AEON?

Which has stronger valuation and earnings, BDRX or AEON?

Does the media favor BDRX or AEON?

Summary

How does Biodexa Pharmaceuticals compare to XTL Biopharmaceuticals?

Which has more risk and volatility, BDRX or XTLB?

Is BDRX or XTLB more profitable?

Which has better valuation & earnings, BDRX or XTLB?

Does the media favor BDRX or XTLB?

Do institutionals & insiders hold more shares of BDRX or XTLB?

Do analysts rate BDRX or XTLB?

Summary

How does Biodexa Pharmaceuticals compare to Soligenix?

Which has more volatility and risk, SNGX or BDRX?

Is SNGX or BDRX more profitable?

Which has stronger valuation and earnings, SNGX or BDRX?

Do analysts prefer SNGX or BDRX?

Does the media prefer SNGX or BDRX?

Do insiders & institutionals hold more shares of SNGX or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Nuvilex?

Which has more volatility & risk, BDRX or PMCB?

Do analysts rate BDRX or PMCB?

Is BDRX or PMCB more profitable?

Which has stronger earnings and valuation, BDRX or PMCB?

Do institutionals & insiders believe in BDRX or PMCB?

Does the media prefer BDRX or PMCB?

Summary

How does Biodexa Pharmaceuticals compare to Cardio Diagnostics?

Which has more risk and volatility, BDRX or CDIO?

Which has better valuation and earnings, BDRX or CDIO?

Does the media prefer BDRX or CDIO?

Do insiders & institutionals believe in BDRX or CDIO?

Is BDRX or CDIO more profitable?

Do analysts rate BDRX or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools